Asset Details
Do you wish to reserve the book?
A randomized trial in patients undergoing percutaneous coronary angioplasty: Roxithromycin does not reduce clinical restenosis but angioplasty increases antibody concentrations against Chlamydia pneumoniae
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A randomized trial in patients undergoing percutaneous coronary angioplasty: Roxithromycin does not reduce clinical restenosis but angioplasty increases antibody concentrations against Chlamydia pneumoniae
Do you wish to request the book?
A randomized trial in patients undergoing percutaneous coronary angioplasty: Roxithromycin does not reduce clinical restenosis but angioplasty increases antibody concentrations against Chlamydia pneumoniae
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A randomized trial in patients undergoing percutaneous coronary angioplasty: Roxithromycin does not reduce clinical restenosis but angioplasty increases antibody concentrations against Chlamydia pneumoniae
2005
Overview
Elevated antibodies against
Chlamydia pneumoniae have been associated with coronary artery disease. In patients undergoing percutaneous coronary angioplasty, we therefore investigated the effect of roxithromycin on symptomatic restenosis and determined antichlamydial antibodies as well as inflammatory and immunological parameters.
A total of 327 patients undergoing coronary angioplasty were randomized to roxithromycin or placebo and followed-up for 1 year. Antibodies were determined by microimmunofluorescence and enzyme-linked immunosorbent assay; C-reactive protein, interleukin-10, tumor necrosis factor-α (TNF-α), and eotaxin were determined by enzyme-linked immunosorbent assay.
Although the frequency of restenosis was not affected by roxithromycin (25 restenoses vs 32 in the control group), antichlamydial antibodies increased during follow-up (anti-CP IgG +12 ± 2%,
P < .001). Concentrations of TNF-α and eotaxin increased as well (TNF-α +9 ± 1% and eotaxin +10 ± 2%) and correlated with antichlamydial antibody concentrations (TNF-α,
r = 0.23,
P = .02; eotaxin,
r = 0.32,
P = .002).
Treatment with roxithromycin was not associated with a reduction of symptomatic restenoses. During follow-up, a marked increase in antichlamydial antibodies, TNF-α, and eotaxin was observed, suggesting that angioplasty-induced plaque rupture induces a specific immunological response without activation of inflammatory mechanisms as represented by C-reactive protein. Whether this mechanism occurs in all plaque ruptures remains to be determined.
Publisher
Mosby, Inc,Elsevier,Elsevier Limited
Subject
/ Angioplasty, Balloon, Coronary
/ Antibiotics. Antiinfectious agents. Antiparasitic agents
/ Biological and medical sciences
/ Chlamydophila pneumoniae - immunology
/ Coronary Restenosis - epidemiology
/ Coronary Restenosis - prevention & control
/ Female
/ Heart
/ Humans
/ Male
/ Pharmacology. Drug treatments
